Olmesartan Pediatric Pharmacokinetic (PK) Study

Inclusion Criteria: * Age 12 months to 16 years inclusive * Signed parental/guardian informed consent and assent from the subject * Current treatment for hypertension, or, if not currently treated for hypertension, systolic blood pressure (SBP) greater than or equal to 95th percentile for gender and height-for-age, or, if not currently treated for hypertension, systolic blood pressure or diastolic blood pressure greater than or equal to 90th percentile for gender and height-for-age and diabetic or having a family history of hypertension * Glomerular filtration rate (GFR) greater than or equal to 30 mL/min/1.73 m2, estimated using the Schwartz equation * Sexually active females of child-bearing potential must be practicing an acceptable method of birth control * Negative serum beta-human chorionic gonadotropin at screening and at admission (female of child-bearing potential only) Exclusion Criteria: * Clinically significant cardiac, gastrointestinal, hematologic, hepatic or hepatobiliary, neurologic, or pulmonary (except asthma) disorder * History of severe or symptomatic hypertension associated with stroke, seizures, encephalopathy, or other significant neurologic findings within 1 year prior to screening * Current treatment with more than 2 antihypertensive medications * Secondary hypertension from uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a single kidney * Serum albumin \< 2.5 g/dL * Major organ or bone marrow transplantation except for prior kidney transplantation of at least 6 months and with stable renal function meeting the inclusion criteria